The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Diabetes Type 2
Initial dose: 0.65 mg subcutaneously once a day for at least 1 week. This dose is intended to reduce gastrointestinal symptoms during initial titration, and is not effective for glycemic control.
After one week, increase the dose to 1.2 mg. If the 1.2 mg dose does not result in acceptable glycemic control, the dose can be increased to 1.8 mg
Renal Dose Adjustments
There is limited experience in patients with mild, moderate, and severe hepatic impairment, including end-stage renal disease. Therefore, liraglutide should be used with caution in this patient population. No dose adjustment of liraglutide is recommended for patients with hepatic impairment.
Liver Dose Adjustments
There is limited experience in patients with mild, moderate, and severe renal impairment, including end-stage renal disease. Therefore, liraglutide should be used with caution in this patient population. No dose adjustment of liraglutide is recommended for patients with renal impairment.
When initiating liraglutide, consider reducing the dose of concomitantly administered insulin secretagogues to reduce the risk of hypoglycemia.
If a dose is missed, the once daily regimen should be resumed as prescribed with the next scheduled dose. An extra dose or increase in dose should not be taken to make up for the missed dose.
Based on the elimination half-life, patients should be advised to reinitiate liraglutide at 0.6 mg if more than 3 days have elapsed since the last dose. This will mitigate any gastrointestinal symptoms associated with reinitiation of treatment. Upon reinitiation, liraglutide should be titrated at the discretion of the healthcare provider.
When using liraglutide with insulin, the injections should be administered separately, never mixed. It is acceptable to inject liraglutide and insulin in the same body region but the injections should not be adjacent to each other.
Liraglutide solution should be inspected prior to each injection, and the solution should be used only if it is clear, colorless, and contains no particles.
Safety and effectiveness have not been established in pediatric patients (less than 18 years of age).
Data not available
The US FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for liraglutide. It includes a communication plan. Additional information is available at www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm111350.htm.